Brian P. McKeon - 08 Nov 2021 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Signature
/s/ Lily J. Lu, Attorney-in-Fact for Brian P. McKeon
Issuer symbol
IDXX
Transactions as of
08 Nov 2021
Net transactions value
-$9,153,176
Form type
4
Filing time
10 Nov 2021, 16:31:41 UTC
Previous filing
09 Aug 2021
Next filing
12 Nov 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $678,500 +10,000 +38% $67.85 36,317 08 Nov 2021 Direct F1
transaction IDXX Common Stock Sale $812,824 -1,300 -3.6% $625.25 35,017 08 Nov 2021 Direct F2
transaction IDXX Common Stock Sale $689,122 -1,100 -3.1% $626.47 33,917 08 Nov 2021 Direct F3
transaction IDXX Common Stock Sale $831,942 -1,326 -3.9% $627.41 32,591 08 Nov 2021 Direct F4
transaction IDXX Common Stock Sale $1,480,024 -2,356 -7.2% $628.19 30,235 08 Nov 2021 Direct F5
transaction IDXX Common Stock Sale $1,318,446 -2,094 -6.9% $629.63 28,141 08 Nov 2021 Direct F6
transaction IDXX Common Stock Sale $612,112 -971 -3.5% $630.39 27,170 08 Nov 2021 Direct F7
transaction IDXX Common Stock Sale $469,122 -743 -2.7% $631.39 26,427 08 Nov 2021 Direct F8
transaction IDXX Common Stock Sale $69,541 -110 -0.42% $632.19 26,317 08 Nov 2021 Direct F9
transaction IDXX Common Stock Options Exercise $428,134 +6,310 +24% $67.85 32,627 09 Nov 2021 Direct
transaction IDXX Common Stock Sale $3,593,652 -5,703 -17% $630.13 26,924 09 Nov 2021 Direct F10
transaction IDXX Common Stock Sale $383,024 -607 -2.3% $631.01 26,317 09 Nov 2021 Direct F11
holding IDXX Common Stock 18,050 08 Nov 2021 by Estony McKeon Family, LLC

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -10,000 -22% 35,535 08 Nov 2021 Common Stock 10,000 $67.85 Direct F12, F13
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -6,310 -18% 29,225 09 Nov 2021 Common Stock 6,310 $67.85 Direct F12, F13
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 9 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on September 30, 2021.
F2 This transaction was executed in multiple trades at prices ranging from $625.00 to $625.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3 This transaction was executed in multiple trades at prices ranging from $626.10 to $627.005. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 This transaction was executed in multiple trades at prices ranging from $627.07 to $628.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5 This transaction was executed in multiple trades at prices ranging from $628.01 to $628.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6 This transaction was executed in multiple trades at prices ranging from $629.10 to $629.97. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7 This transaction was executed in multiple trades at prices ranging from $630.03 to $630.98. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8 This transaction was executed in multiple trades at prices ranging from $631.10 to $631.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9 This transaction was executed in multiple trades at prices ranging from $632.01 to $632.36. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10 This transaction was executed in multiple trades at prices ranging from $630.00 to $631.00. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F11 This transaction was executed in multiple trades at prices ranging from $631.005 to $631.49. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F12 Grant of option to buy 45,535 shares of IDEXX Laboratories, Inc. common stock that vested in five annual installments beginning February 14, 2017.
F13 Not applicable.